(Q35094901)

6 August 2017

1 reference

title

Designing neuroprotection trials in Parkinson's disease (English)

1 reference

6 August 2017

1 reference

1

Karl Kieburtz

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

53 Suppl 3

1 reference

6 August 2017

page(s)

S100-7; discussion S107-9

1 reference

The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living

6 August 2017

cites work

1 reference

Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany.

21 January 2018

1 reference

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

21 January 2018

1 reference

Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential i

21 January 2018

1 reference

DBS and diathermy interaction induces severe CNS damage.

21 January 2018

1 reference

Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.

21 January 2018

1 reference

Antecedent clinical features associated with dementia in Parkinson's disease

21 January 2018

1 reference

Risk of dementia in Parkinson's disease: a community-based, prospective study.

21 January 2018

1 reference

Accuracy of self-reported disability in patients with parkinsonism.

21 January 2018

1 reference

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

21 January 2018

1 reference

4 November 2023

https://opencitations.net/index/coci/api/v1/citations/10.1038/33416

Identifiers

DOI

10.1002/ANA.10484

1 reference

6 August 2017

1 reference